Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL1010410

C(=C1CCNCC1)c1cccc(Oc2ccccn2)c1.O=C(O)C(F)(F)F

nearest known ligand 0.51

Full drug profile on Sugi Atlas →

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
FAAH O00519 17/20 0.51
TLR4 O00206 1/20 0.45
TLR2 O60603 1/20 0.45
CYP3A4 P08684 4/20 0.44
CYP2D6 P10635 3/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44
GABRA1 P14867 1/20 0.44
ADRA2C P18825 1/20 0.44
CNR1 P21554 1/20 0.44
HTR2A P28223 1/20 0.44
HTR2C P28335 1/20 0.44
CNR2 P34972 1/20 0.44
HTR2B P41595 1/20 0.44
TMEM97 Q5BJF2 1/20 0.44
SIGMAR1 Q99720 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27233571 0.89 TLR4 (0.51) FAAHTLR4TLR2CYP3A4CYP2C9
Trifluoroacetic Acid SCHEMBL1011595 0.86 FAAH (0.52) FAAHCYP3A4CYP2D6CYP2C9
Trifluoroacetic Acid SCHEMBL1011484 0.85 FAAH (0.51) FAAHCYP3A4CYP2C9CYP2C19
Trifluoroacetic Acid SCHEMBL1011442 0.84 FAAH (0.54) FAAHCYP3A4CYP2C9CYP2C19
Trifluoroacetic Acid SCHEMBL1011081 0.84 FAAH (0.50) FAAHCYP2C9
Trifluoroacetic Acid SCHEMBL1012037 0.81 FAAH (0.43) FAAHCYP2C9
Trifluoroacetic Acid SCHEMBL1011579 0.80 KDM4E (0.54)
SCHEMBL30657588 0.79 FAAH (0.51) FAAHTLR4TLR2CYP3A4CYP2D6
SCHEMBL27094605 0.79 FAAH (0.51) FAAHTLR4TLR2CYP3A4CYP2D6
SCHEMBL1011526 0.77 FAAH (0.62) FAAHCYP3A4CYP2D6CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8044052-B2 Inhibitors of fatty acid amide hydrolase; N-pyridin-3-yl-4-(3-{[5-(trifluoromethyl)pyridin-2-yl]oxy}benzylidene)piperidine-1-carboxamide; elevate brain anandamide levels; pain, urinary incontinence, cognitive disorders, anxiety, depression, sleeping, eating, movement disorders, glaucoma, psoriasis PFIZER INC. (US) 2011-10-25 US disclosed
EP-2076508-B1 BIARYL ETHER UREA COMPOUNDS PFIZER PROD INC (US) 2011-01-05 EP disclosed
EP-2076508-A2 BIARYL ETHER UREA COMPOUNDS Pfizer Products Inc. (US) 2009-07-08 EP disclosed
US-20080261941-A1 Biaryl Ether Urea Compounds Jazz Pharmaceuticals Therapeutics, Inc. 2008-10-23 US disclosed
WO-2008047229-A2 BIARYL ETHER UREA COMPOUNDS PFIZER PRODUCTS INC. (US) 2008-04-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080261941-A1 Biaryl Ether Urea Compounds FAAH, FAAH2, LIPC FAAH 1/4885TLR4 4184/4885TLR2 4044/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.